Lilly's Retatrutide Yields 50-Pound Loss
Lilly's experimental GLP-1 drug retatrutide has shown significant weight-loss results, with participants taking the 12 mg dose losing nearly 50 pounds over 80 weeks, including more weight loss in individuals with higher BMI. The company plans to seek FDA approval for retatrutide as a biologic medication, potentially extending market exclusivity, and is exploring its use for treating obstructive sleep apnea.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)